Oncol Case Rep J | Volume 5, Issue 1 | Case Report | Open Access
Bindiya G Patel*, Samantha Conlin, Syed Usman M Ehsanullah and Siddhartha Devarakonda
Department of Hematology-Oncology, Washington University School of Medicine, USA
*Correspondance to: Bindiya G Patel
Fulltext PDFHepatoid Thymic Carcinoma (HTC) is a very rare subtype of thymic carcinoma with aggressive clinical course. HTC demonstrates polygonal tumor cells appearing like hepatocytes and expresses Hep-Par-1. In this case report, we describe a patient with HTC who responded to treatment with immune checkpoint inhibitor pembrolizumab after failing treatment with chemoradiation and targeted therapy with lenvatinib, a multiple kinase inhibitor. Next generation sequencing of the patient’s tumor tissue demonstrated a mutation in SMARCA4. Review of relevant literature suggests that SMARCA4 alteration maybe associated with higher likelihood of immune checkpoint inhibitor response.
Patel BG, Conlin S, Ehsanullah SUM, Devarakonda S. Hepatoidthymic Carcinoma: A Case Report of Response to Immune Checkpoint Inhibitor. Oncol Case Report J. 2022;5(1):1044..